Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05625464 · ClinicalTrials.gov registry record · NA
Effect of Automated Real-time Feedback on Early Sepsis Care
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 3,269
- Enrollment target
NCT05625464: Completed NA study, sponsored by Massachusetts General Hospital.
NCT05625464 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 3,269 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05625464, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 3,269 participants
- Enrollment target
Study Summary
Sepsis is the leading cause of death among US hospitals, accounting for 6% of all hospitalizations and 35% of all inpatient deaths. International guidelines and the CMS SEP-1 bundle stress the importance of adhering to specific steps in the diagnosis and management of sepsis. This can be very difficult, especially in the setting of a busy ED, ward, or ICU where there are multiple simultaneous demands on providers' attention and time. Critical steps can be missed or delayed. The CMS SEP-1 bundle is a measure of compliance with sepsis care that is being tracked nationally across hospitals. Unfortunately, a recent study demonstrated that every hour of delay to the completion of a sepsis bundle, including antibiotic administration, was associated with a 4% increase in risk-adjusted hospital mortality. One strategy to improve the care and outcomes of patients with sepsis is the use of information technology to support our providers in a targeted manner. Technology has already been developed and deployed to help with the early identification of patients with sepsis using a Best Practice Alert (BPA), which has been in place at our hospital since 2017. This pop-up window alerts the team to the possibility of sepsis based on data within the medical record. However, once the alert is accepted or declined, the BPA does not offer ongoing support to clinicians, leaving the clinician to track and execute multiple time-based and inter-dependent sepsis bundle measures in a busy, hectic environment. To augment this existing tool, here we propose to study the efficacy of a novel technology called the Sepsis Care Tracking Platform (SCTP) to provide ongoing support at the bedside to providers, thus improving the care we deliver to patients. SCTP is a monitoring and notification platform that aims to increase the timely delivery of key elements of evidence-based sepsis care. This platform, which was built by clinicians for clinicians, leverages the electronic medical record (EMR) to
Interventions
- OTHER SCTP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,269 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2021-11-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05625464
The ClinicalTrials.gov registry entry for NCT05625464 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 3,269 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SCTP is the first listed.
NCT05625464 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05625464 about?
NCT05625464 is a clinical study titled "Effect of Automated Real-time Feedback on Early Sepsis Care". Sepsis is the leading cause of death among US hospitals, accounting for 6% of all hospitalizations and 35% of all inpatient deaths. International guidelines and the CMS SEP-1 bundle stress the importance of adhering to specific steps in the diagnosis and management of sepsis. This can be very diffic...
What is the current status of trial NCT05625464?
This trial is currently completed. It is a NA study. The enrollment target is 3,269 participants. The study started on 2020-12-01. Estimated completion is 2021-11-30.
What interventions are being tested in trial NCT05625464?
The interventions under investigation include: SCTP (OTHER).
Who is sponsoring clinical trial NCT05625464?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.